Author

R. S. Avedian

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

D. G. Mohler· 2 shared A. G. Lee· 1 shared A. L. Koehne· 1 shared A. Spillinger· 1 shared A. T. Shah· 1 shared C. Curtis· 1 shared C. Luck· 1 shared C. R. Schott· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. G. Mohler

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities

C. R. Schott, A. L. Koehne, L. C. Sayles, E. P. Young, C. Luck, K. Yu, A. G. Lee, M. R. Breese, S. G. Leung, A. T. Shah, H. Xu, H.-Y. Liu, A. Spillinger, I. H. Behroozfard, K. D. Marini, , E. A. Sweet-Cordero

The paper develops and characterizes new osteosarcoma PDX models with varying metastatic capacities to study disease biology and test therapeutic interventions.

bioRxiv · Jan 19, 2023Cancer Biology

Interactions in CSF1-driven Tenosynovial Giant Cell Tumors

D. G. P. van IJzendoorn, M. Matusiak, G. W. Charville, G. Spierenburg, S. Varma, D. R. C. Colburg, M. A. J. van de Sande, K. van Langevelde, D. G. Mohler, K. N. Ganjoo, N. Q. Bui, R. S. Avedian, J. V. M. G. Bovee, R. Steffner, R. B. West, M. van de Rijn

The paper identifies GFPT2 as a marker for synoviocytes in TGCT and shows neoplastic cells lack CSF1R, suggesting current therapies may not target them effectively.

bioRxiv · Jun 1, 2022Cancer Biology